Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis

In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and...

Descripción completa

Detalles Bibliográficos
Autores principales: Westerberg, Per-Anton, Linde, Torbjörn, Vanderschueren, Dirk, Billen, Jaak, Jans, Ivo, Ljunggren, Östen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400509/
https://www.ncbi.nlm.nih.gov/pubmed/26069775
http://dx.doi.org/10.1093/ckj/sfs031
Descripción
Sumario:In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

Ejemplares similares